Abstract
This phase II/III trial tests the safety, side effects, and best dose of the drug
cabozantinib in combination with standard chemotherapy, and to compare the effect of adding
cabozantinib to standard chemotherapy alone in treating patients with newly diagnosed
osteosarcoma. Cabozantinib is in a class of medications called kinase inhibitors which block
protein signals affecting new blood vessel formation and the ability to activate growth
signaling pathways. This may help slow the growth of tumor cells. The drugs used in standard
chemotherapy for this trial are methotrexate, doxorubicin, and cisplatin (MAP). Methotrexate
stops cells from making DNA and may kill tumor cells. It is a type of antimetabolite.
Doxorubicin is in a class of medications called anthracyclines. It works by slowing or
stopping the growth of tumor cells in the body. Cisplatin is in a class of medications known
as platinum-containing compounds. It works by killing, stopping or slowing the growth of
tumor cells. Adding cabozantinib to standard chemotherapy may work better in treating newly
diagnosed osteosarcoma.

